Literature DB >> 28336396

Tumor Control Index as a new tool to assess tumor growth in experimental animals.

William L Corwin1, Hakimeh Ebrahimi-Nik1, Stephanie M Floyd1, Pouya Tavousi2, Ion I Mandoiu3, Pramod K Srivastava4.   

Abstract

Measurement of tumor diameters, tumor volumes, or area under the curve has been traditionally used to quantitate and compare tumor growth curves in immune competent as well as immune-compromised mice and rats. Here, using tumor growth data from a large number of mice challenged with live tumor cells, we describe the use of a new composite parameter, Tumor Control Index (TCI) as an alternative method to do the same. This index, comprised of three distinct values, the Tumor Inhibition Score, Tumor Rejection Score, and Tumor Stability Score, provides a complete picture of nearly every aspect of tumor growth in large numbers of animals, can be deduced automatically from tumor diameter or volume data, and can be used to compare several groups of animals in different experiments. This automatically derivable index also corresponds neatly to the use of complete and partial responses and tumor stability data generated in human tumors, and can be used to assess the efficacy of interventions to be used in clinical studies.
Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Area under the curve; Immunotherapy; Mice; PDX models; Rats; Vaccination

Mesh:

Year:  2017        PMID: 28336396     DOI: 10.1016/j.jim.2017.03.013

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  6 in total

1.  Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1).

Authors:  Mei-Chun Yeh; Brian W C Tse; Nicholas L Fletcher; Zachary H Houston; Maria Lund; Marianna Volpert; Chelsea Stewart; Kamil A Sokolowski; Varinder Jeet; Kristofer J Thurecht; Douglas H Campbell; Bradley J Walsh; Colleen C Nelson; Pamela J Russell
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

2.  Mass spectrometry driven exploration reveals nuances of neoepitope-driven tumor rejection.

Authors:  Hakimeh Ebrahimi-Nik; Justine Michaux; William L Corwin; Grant Lj Keller; Tatiana Shcheglova; HuiSong Pak; George Coukos; Brian M Baker; Ion I Mandoiu; Michal Bassani-Sternberg; Pramod K Srivastava
Journal:  JCI Insight       Date:  2019-06-20

3.  Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation.

Authors:  Marianna Volpert; Brett G Hollier; Yu Hin Tang; Anja Rockstroh; Kamil A Sokolowski; Layla-Rose Lynam; Melanie Lehman; Erik W Thompson; Philip A Gregory; Colleen C Nelson
Journal:  Breast Cancer Res       Date:  2022-01-25       Impact factor: 6.466

4.  Approximating net interactions among rigid domains.

Authors:  Pouya Tavousi
Journal:  PLoS One       Date:  2018-04-09       Impact factor: 3.240

5.  CD11c+ MHCIIlo GM-CSF-bone marrow-derived dendritic cells act as antigen donor cells and as antigen presenting cells in neoepitope-elicited tumor immunity against a mouse fibrosarcoma.

Authors:  Hakimeh Ebrahimi-Nik; William L Corwin; Tatiana Shcheglova; Alok Das Mohapatra; Ion I Mandoiu; Pramod K Srivastava
Journal:  Cancer Immunol Immunother       Date:  2018-07-20       Impact factor: 6.968

6.  Quantifying relative virulence: when μ max fails and AUC alone just is not enough.

Authors:  Ruben Michael Ceballos; Carson Len Stacy
Journal:  J Gen Virol       Date:  2020-11-05       Impact factor: 3.891

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.